A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PALOMA-2)
Purpose of Study:The primary objectives are to assess anti-tumor activity (objective response rate [ORR]) (Cohorts 1, 2, and 3) and to evaluate the safety (Cohort 4) of amivantamab SC-CF via manual injection.
December 2, 2022 - May 31, 2024
Type of Study:
Janssen Research & Development, LLC
Sponsors:Janssen Research & Development, LLC
Email: [email protected]